dactinomycin + cyclophosphamide + vincristine

The combination of dactinomycin, cyclophosphamide, and vincristine, commonly known as the VAC regimen, is a multi-agent chemotherapy protocol primarily utilized in the management of pediatric solid tumors, including rhabdomyosarcoma, Ewing sarcoma, and Wilms tumor. Dactinomycin (actinomycin D) is a cytotoxic antibiotic that intercalates into DNA, thereby inhibiting RNA synthesis. Cyclophosphamide is an alkylating agent that forms DNA cross-links, interfering with DNA replication and transcription. Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and causing mitotic arrest in the metaphase. Although the input name associates this combination with Yonsei University and gastric adenocarcinoma, clinical evidence and the provided trial context (NCT00543556) indicate that the actual regimen studied for this indication at Yonsei University is DCS (docetaxel, cisplatin, and S-1). There is no established clinical use for the dactinomycin, cyclophosphamide, and vincristine combination in the treatment of gastric adenocarcinoma.

Other names

Actinomycin D + Cyclophosphamide + VincristineVincristine + Actinomycin D + Cyclophosphamide